Robert T. Jones - Concepedia

Author

Robert T. Jones

Also Known As

R JONES, R Jones, R. Jones, R. T. Jones, R.T. Jones, Robert Jones, Robert T Jones, Robert T. Jones, Robert Treharne Jones

Publications

4.2K

Citations

H-Index

Concepts

All Affiliations

Dana-Farber Cancer Institute Broad Institute Harvard University Brigham and Women's Hospital Massachusetts General Hospital

About

Robert T. Jones is an author at Dana-Farber Cancer Institute specializing in medicine, pathology, and tumor biology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	7	7	1.1K
2	Cell Biology	2	2	156
3	Health Sciences	1	1	90
4	Public Health	1	1	35
5	Immunology	1	1	66

Robert T. Jones

Publications

4.1K

Citations

H-Index

Page 1

	Year	Citations
Genomic Characterization of Brain Metastases Reveals Branched Evolution and Potential Therapeutic Targets Priscilla K. Brastianos, Scott L. Carter, Sandro Santagata, Cancer Discovery	2015	1.1K
Genomic sequencing of meningiomas identifies oncogenic SMO and AKT1 mutations Priscilla K. Brastianos, Peleg Horowitz, Sandro Santagata, Nature Genetics	2013	629
Exome sequencing identifies BRAF mutations in papillary craniopharyngiomas Priscilla K. Brastianos, Amaro Taylor‐Weiner, Peter Manley, Nature Genetics Somatic VariantMedicineGeneticsPathologyIdentifies Braf Mutations	2014	503
<i>RAS</i> Mutations Are Associated With the Development of Cutaneous Squamous Cell Tumors in Patients Treated With RAF Inhibitors Patrick A. Oberholzer, Damien Kee, Piotr Dziunycz, Journal of Clinical Oncology	2011	378
Somatic mutation of CDKN1B in small intestine neuroendocrine tumors Joshua M. Francis, Adam Kieżun, Alex H. Ramos, Nature Genetics Endocrine OncologySomatic MutationPathologyNeuroendocrine TumorsMedicine	2013	365
Oncogenic mutations in cervical cancer Alexi A. Wright, Brooke E. Howitt, Andrea P. Myers, Cancer	2013	268
Inhibition of the CCL2 receptor, CCR2, enhances tumor response to immune checkpoint therapy Megan M. Tu, Hany Abdel-Hafiz, Robert T. Jones, Communications Biology	2020	157
Targeting DDR2 enhances tumor response to anti–PD-1 immunotherapy Megan M. Tu, Francis Y. F. Lee, Robert T. Jones, Science Advances	2019	124
Sporadic hemangioblastomas are characterized by cryptic VHL inactivation Ganesh M. Shankar, Amaro Taylor‐Weiner, Nina Lelic, Acta Neuropathologica Communications Vascular MalformationPathologyTumor BiologyCryptic Vhl InactivationNeuro-oncology	2014	90
Mitogenic and progenitor gene programmes in single pilocytic astrocytoma cells Zachary J. Reitman, Brenton R. Paolella, Guillaume Bergthold, Nature Communications	2019	89

Page 1